An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

Phase 3TerminatedNCT02258854

XOMA (US) LLC69 enrolled

Overview

The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Uveitis

Interventions

Dose 2 gevokizumabDRUG

Solution for subcutaneous injection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completed either the X052130/CL3-78989-005 or the X052131/CL3-78989-006 study's masked D392 or OL-224 completion day visits or had controlled ocular inflammation after having received study drug in Part 2 of study X052133 Exclusion Criteria: * Discontinued from the previous study Other protocol-defined inclusion/exclusion criteria may apply

Locations (33)

Unnamed facility

Chandler, Arizona, United States

Outcomes

Primary Outcomes

Treatment-emergent Adverse Events

Time frame: 108 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.